vHROGENETICS 
K 
"Nonreplicating Viral Vectors as Potential Vaccines: Recombinant 
Canarypox Virus Expressing Measles Virus Fusion (F) and Heamgglutinin 
(HA) Glycoproteins", Taylor etal., Virology, 187:321-328 (1992). This 
paper presents data demonstrating protection induced in dogs against Canine 
Distemper Virus (CDV) challenge after inoculation with an ALVAC-based 
recombinant. 
L 
Report demonstrating that pre-existing immunity to canarypox virus does 
not preclude immune responses to novel antigens expressed by ALVAC- 
based vaccines. 
M 
Two parts: 1) "Human safety and immunogenicity of a canarypox-rabies 
glycoprotein recombinant vaccine: an alternative pox virus vector system", 
Fries, et al., submitted for publication. 2) Evaluation of safety and 
immunogenicity of ascending doses of ALVAC-RG (vCP65) in healthy 
adult human volunteers. Study performed at Johns Hopkins Center for 
Immunization Research. 
N 
"Immunization with canarypox virus expressing the rabies glycoprotein", 
Cadoz, et al.. Lancet, 339:1429-1432 (1992). This paper documents a 
clinical trial involving twenty-five human volunteers in which ALVAC-RG 
(vCP65) was found to be safe and well-tolerated. Original data is appended 
to the article. This study was performed at Centre Hospitalier Rdgionale et 
Universitaire de Reims, France. 
O 
A letter from Dr. Cyril Gay of USD A/ APHIS, granting Virogenetics a 
Biosafety Level- 1 for a contained release involving an ALVAC-based 
Japanese Encephalitis Virus vaccine (vCP107) to be administered to 150 
swine at Purdue University. 
OTHER 
REFERENCES 
Recombinant Poxviruses , M. Binns and G. Smith, 
editors; CRC Press, Boca Raton, Florida, 1992. 
[168] 
Recombinant DNA Research, Volume 18 
